Isoxazoline parasiticide formulations and methods for treating blepharitis
AssigneeTarsus Pharmaceuticals, Inc.
InventorsBobak Robert Azamian, Douglas Michael Ackermann, Shawn D. Hickok, Joseph G. Vehige
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Claims30
(canceled)
An isoxazoline parasiticide ophthalmic composition comprising lotilaner,
- wherein the lotilaner is present from about 0.10% to about 0.50% by weight with respect to the total weight of the composition, and
- wherein the composition is in eye drop form.
An isoxazoline parasiticide ophthalmic composition comprising:
- lotilaner, wherein the lotilaner is present from about 0.10% to about 0.50% by weight with respect to the total weight of the composition;
- a hydrogenated castor oil;
- and
- a polysaccharide thickener.
An isoxazoline parasiticide ophthalmic composition comprising lotilaner, wherein the ophthalmic composition is in eye drop form, and wherein the ophthalmic composition is only locally therapeutically effective.
An isoxazoline parasiticide ophthalmic composition comprising lotilaner, wherein the ophthalmic composition is formulated as a gel, an ointment, or a cream, and wherein the ophthalmic composition is only locally therapeutically effective.
Dependencies are inferred from the claim text.